Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
ConclusionDupilumab significantly improved AD signs, symptoms and quality of life in children aged 6 months to 5 years with severe AD with acceptable safety.Trial RegistrationThe trial was registered with ClinicalTrials.gov with ID number NCT03346434, part B. (Source: Advances in Therapy)
Source: Advances in Therapy - January 9, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative Safety of Pulsed Field Ablation and Cryoballoon Ablation Technologies for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: A Critical Literature Review and Indirect Treatment Comparison
ConclusionThe findings of this study show that PFA has a more favorable safety profile than CBA, with significantly lower risks of major and prespecified adverse events. These indirect comparisons help contextualize the safety of PFA compared to CBA for the treatment of drug-refractory PAF in the absence of head-to-head studies. (Source: Advances in Therapy)
Source: Advances in Therapy - January 8, 2024 Category: Drugs & Pharmacology Source Type: research
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
This study supports rocatinlimab as a potentially safe and effective treatment for moderate-to-severe AD. (Source: Advances in Therapy)
Source: Advances in Therapy - January 8, 2024 Category: Drugs & Pharmacology Source Type: research
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing
ConclusionIVT-AFL T&E can achieve similar functional and anatomic outcomes to fixed dosing every 8 weeks over 52 weeks in patients with nAMD who have completed ≥ 1 year of treatment, while reducing treatment burden.Trial RegistrationClinicalTrials.gov Identifier: NCT02540954. (Source: Advances in Therapy)
Source: Advances in Therapy - January 6, 2024 Category: Drugs & Pharmacology Source Type: research
Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1)
ConclusionsCTC demonstrated superior pain relief compared with tramadol or placebo, as well as an improved benefit/risk profile versus tramadol.Trial registrationClinicalTrials.gov identifier, NCT02982161; EudraCT number, 2016-000592-24. (Source: Advances in Therapy)
Source: Advances in Therapy - January 6, 2024 Category: Drugs & Pharmacology Source Type: research
A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants
ConclusionsResults of the study showed PK and PD bioequivalence of pegfilgrastim-cbqv administered using OBI compared with PFS. OBI and PFS administration had similar safety, tolerability, and immunogenicity profiles. No unexpected safety signals were identified.Graphical Abstract available for this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - January 5, 2024 Category: Drugs & Pharmacology Source Type: research
Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus
ConclusionGLP-1R rs10305420 polymorphism can explain some of the inter-individual differences in glycemic response to liraglutide in a population of Iranian people with T2DM. (Source: Advances in Therapy)
Source: Advances in Therapy - January 4, 2024 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes
ConclusionsBT-001 plus SoC was estimated to dominate SoC alone over the lifetime horizon from a payer perspective, suggesting that using BT-001 can empower patients to better manage their diabetes with the potential for lifelong advantages. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research
TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort
ConclusionThis is the first study in Colombia (TIROSEC) to our knowledge that integrates molecular and histopathologic profiles enriching our local comprehension and knowledge of PTC. The identification of target mutations such asBRAF,RET andNTRK fusions holds the potential to guide targeted therapies for tumor recurrence and predict aggressive behavior. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research
Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years
This study supports the effectiveness of Oleogel-S10 in a real-world scenario in a country with scarce resources for the trea tment of EB. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
ConclusionAn 8-week regimen of GLE/PIB is well tolerated and highly effective among US patients with HCV and cirrhosis receiving routine clinical care. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study
ConclusionsWe identified a glaucoma subgroup in which PR decreased, choroidal blood flow increased, and glaucoma progression slowed after a β-blocker eye drop add-on was started. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
ConclusionResponse to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
Immune Cell Alterations and PI3K-PKB Pathway Suppression in Patients with Allergic Rhinitis Undergoing Sublingual Immunotherapy
ConclusionOur study has demonstrated that SLIT treatment led to distinct changes in immune cell profiles between mono-sensitized and poly-sensitized AR patients. Furthermore, SLIT appeared to reduce a Th2 immune response, highlighting its efficacy in AR treatment. Importantly, the study revealed the suppression of the PI3K-PKB pathway, shedding light on the immunological mechanisms underlying SLIT ’s effectiveness. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
ConclusionMost studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
